NOVOLOG MIX 50/50
LOE ApproachingBLASUBCUTANEOUSINJECTABLE
Approved
Aug 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVOLOG MIX 50/50 is a premixed insulin combination containing 50% insulin aspart and 50% insulin aspart protamine suspension, administered subcutaneously for glycemic control in patients with diabetes. This fixed-ratio formulation simplifies insulin therapy by combining rapid-acting and intermediate-acting insulins in a single injection. It is indicated for patients with type 1 or type 2 diabetes who require basal-bolus insulin regimens.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting defensive commercial strategy and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NOVOLOG MIX 50/50 offers experience in managing a mature, legacy insulin product in a highly competitive market with declining growth prospects. Career advancement may be limited by the product's lifecycle stage; professionals should consider this a consolidation or defensive strategy role rather than a high-growth opportunity.
Brand ManagerField Sales Representative
Worked on NOVOLOG MIX 50/50 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.